$1.8 B

ATRA Mkt cap, 04-Dec-2018
Atara Biotherapeutics Net income (Q1, 2018)-41.4 M
Atara Biotherapeutics EBIT (Q1, 2018)-42.5 M
Atara Biotherapeutics Cash, 31-Mar-201890.5 M

Atara Biotherapeutics Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

R&D expense

241.0k41.6m56.5m81.2m

General and administrative expense

834.0k16.8m24.7m40.3m

Operating expense total

1.1m58.4m81.2m121.5m

EBIT

(4.1m)(58.4m)(81.2m)(121.5m)

Interest income

125.0k1.2m2.2m2.0m

Pre tax profit

(4.1m)(57.2m)

Income tax expense

17.0k(9.0k)10.0k(14.0k)

Net Income

(4.1m)(57.2m)(79.0m)(119.5m)

Quarterly

USDQ2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

R&D expense

7.0m11.2m13.0m18.8m17.5m18.3m20.6m28.5m

General and administrative expense

3.6m5.8m6.5m7.1m8.6m9.6m11.1m14.0m

Operating expense total

15.1m17.1m19.5m25.9m26.2m27.9m31.7m42.5m

EBIT

(15.1m)(17.1m)(19.5m)(25.9m)(26.2m)(27.9m)(31.7m)(42.5m)

Interest income

163.0k503.0k605.0k576.0k509.0k481.0k564.0k1.0m

Pre tax profit

(14.9m)(16.6m)(18.9m)(25.7m)(27.4m)(31.1m)(41.4m)

Income tax expense

3.0k3.0k7.0k

Net Income

(14.9m)(16.6m)(18.9m)(25.4m)(25.7m)(27.4m)(31.1m)(41.4m)

Atara Biotherapeutics Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017

Cash

23.7m48.0m79.2m

Inventories

3.9m4.7m

Current Assets

324.6m260.6m172.2m

PP&E

270.0k3.3m44.1m

Total Assets

325.0m263.9m217.8m

Accounts Payable

1.4m2.8m14.7m

Current Liabilities

9.7m9.7m27.6m

Total Liabilities

10.2m39.9m

Additional Paid-in Capital

413.7m431.1m474.7m

Retained Earnings

(98.1m)(177.2m)(296.6m)

Total Equity

315.1m253.7m177.9m

Financial Leverage

1 x1 x1.2 x

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

26.2m54.5m22.1m26.4m46.0m62.4m64.2m60.5m90.5m

Current Assets

160.6m340.2m311.7m298.9m282.2m235.3m222.5m206.2m413.6m

PP&E

42.0k46.0k1.1m1.8m2.1m4.4m20.3m22.2m58.2m

Total Assets

161.1m340.4m313.0m300.8m284.4m241.7m244.2m229.7m473.1m

Accounts Payable

1.7m1.9m1.9m3.2m4.5m2.2m5.2m5.5m6.1m

Current Liabilities

11.6m6.5m8.9m10.0m13.7m7.8m11.5m16.5m21.0m

Total Liabilities

11.8m6.6m9.1m10.6m14.2m8.6m23.0m23.7m33.9m

Additional Paid-in Capital

214.3m410.6m418.5m423.6m429.1m436.1m451.5m467.4m777.8m

Retained Earnings

(65.0m)(76.9m)(114.7m)(133.6m)(158.9m)(202.8m)(230.2m)(261.3m)(338.1m)

Total Equity

149.3m333.7m303.8m290.2m270.2m233.1m221.1m206.0m439.2m

Financial Leverage

1.1 x1 x1 x1 x1.1 x1 x1.1 x1.1 x1.1 x

Atara Biotherapeutics Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(4.1m)(57.2m)(79.0m)(119.5m)

Depreciation and Amortization

48.0k383.0k956.0k

Accounts Payable

1.0m981.0k2.2m

Cash From Operating Activities

(37.2m)(60.0m)(87.5m)

Purchases of PP&E

(290.0k)(3.0m)(20.2m)

Cash From Investing Activities

(220.1m)83.7m98.7m

Cash From Financing Activities

259.2m506.0k20.0m

Income Taxes Paid

3.0k10.0k

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018

Net Income

(24.1m)(16.6m)(35.4m)(60.8m)(25.7m)(84.2m)(41.4m)

Depreciation and Amortization

11.0k15.0k79.0k210.0k678.0k333.0k

Accounts Payable

1.2m1.9m451.0k1.8m3.0m2.2m(1.0k)(2.1m)

Cash From Operating Activities

(12.9m)(12.5m)(23.3m)(38.9m)(62.6m)(34.8m)

Purchases of PP&E

(5.0k)(891.0k)(1.6m)(2.0m)(10.5m)(19.8m)

Cash From Investing Activities

(47.8m)10.9m25.9m61.0m55.7m(249.9m)

Cash From Financing Activities

65.0m(18.0k)(24.0k)175.0k19.4m296.0m

Income Taxes Paid

3.0k3.0k10.0k

Atara Biotherapeutics Ratios

USDY, 2018

Financial Leverage

1.1 x
Report incorrect company information

Atara Biotherapeutics Operating Metrics

FY, 2016

Phase I Trials Products

3

Phase II Trials Products

3

Phase III Trials Products

1
Report incorrect company information

Atara Biotherapeutics Employee Rating

3.24 votes
Culture & Values
3.4
Work/Life Balance
3.7
Senior Management
3.4
Salary & Benefits
4.3
Career Opportunities
4.4
Source